This event will explore the vision behind the Infinite Games and outline what participants can expect from the Longevity Olympics series. It will also highlight current breakthroughs in the science of aging and the emerging field of biomarkers, which provide measurable indicators of how well the body is maintaining or losing function over time. Together these sessions establish the foundation for a new approach to human health and performance, where collective data helps map the pathways toward longer and stronger lives.
To be a Longevity Biomarker Athlete make sure to register here.
https://luma.com/RejuveAI2026
SUMMIT
3PM - 8PM Networking, Friday, February 6
9AM - 5PM Talks, Saturday, February 7
7PM - 11PM Longevity Rave, Saturday, February 7
9AM - 4PM Talks, Sunday, February 8
More detailed agenda coming soon!
Dr. Macsue Jacques (Rejuve.AI / Australian Regenerative Medicine Institute)
Dr. Macsue Jacques is a scientist specializing in regenerative medicine and biological aging. Her work focuses on translational longevity research, clinical biomarker development, and innovation in aging-related clinical studies. She is a Research Fellow at the Australian Regenerative Medicine Institute and contributes to scientific leadership and strategy at Rejuve.AI.
Jasmine Smith (Rejuve.AI)
Jasmine Smith is the Founding CEO of Rejuve.AI, a platform pioneering decentralized, AI-driven longevity research and data ownership. She leads Rejuve.AI’s community, product, and protocol development, advocating for accessible healthspan technologies and citizen-powered science. Jasmine has presented at major global longevity events and is recognized for advancing participatory approaches to biomarker discovery.
Niklas Anzinger (Infinita City / Infinita VC)
Niklas Anzinger is the Founder & CEO of Infinita City and General Partner of Infinita VC, based in Próspera, Honduras. His work centers on regulatory innovation, competitive governance, and accelerating frontier biotech and longevity ventures. He also hosts the Stranded Technologies podcast, exploring how new governance models unlock scientific and technological progress.
Tina Woods (Collider Health / Business for Health)
Tina Woods is a social entrepreneur and systems innovator in health and longevity. She is Founder & CEO of Collider Health and co-founder of Business for Health, leading initiatives that integrate prevention, data-driven health strategy, and ESG frameworks. As the Healthy Longevity Champion at the UK National Innovation Centre for Ageing, she co-leads national efforts to accelerate healthspan innovation. She is also the author of Live Longer with AI.
Dr. Andrea Cipriano (Stanford School of Medicine / Biomarkers of Aging Consortium)
Dr. Andrea Cipriano is a researcher at Stanford University School of Medicine specializing in stem cell biology, epigenetic aging, and translational biomarkers. As a key member of the Biomarkers of Aging Consortium, she contributes to standardizing and validating biological age metrics across omics and clinical data. Her work includes research on the PRC2-AgeIndex and applications of epigenetic biomarkers in regenerative medicine.
Dr. Eric Verdin
Dr. Eric Verdin is President and CEO of the Buck Institute for Research on Aging and a leading scientist in the biology of aging, epigenetics, and metabolism. His research focuses on how chromatin regulation, immune function, and metabolic pathways influence aging and age-related disease, with the goal of translating basic science into interventions that extend healthy lifespan.
Ivan Morgunov (Unlimited Bio)
Ivan Morgunov is the Founder and CEO of Unlimited Bio, a gene-therapy company based in Próspera, Roatán, developing combination gene therapies aimed at rejuvenation and prevention of age-related decline. Unlimited Bio’s work includes VEGF-based and other experimental therapies delivered in innovation-friendly jurisdictions, with a focus on engineering multi-pathway interventions rather than single-target drugs.
David Barzilai (Agingdoc)
Dr. David Barzilai is a physician and longevity-focused clinician working at the intersection of preventative medicine, health optimization, and emerging longevity science. He is known for translating cutting-edge research into practical, patient-centered approaches to extending healthspan, with an emphasis on biomarkers, lifestyle interventions, and responsible use of novel longevity technologies.
Dr. Mahdi Moqri (Biomarkers of Aging Consortium)
Dr. Mahdi Moqri is a computational biologist and aging researcher with appointments at Harvard Medical School, Brigham and Women’s Hospital, and affiliations with Stanford’s Department of Genetics. He serves in a leadership role at the Biomarkers of Aging Consortium, where he helps drive consensus frameworks and validation standards for biological aging measures across multi-omics and clinical data.
Partners and Sponsors
Rejuve.AI is an AI-driven longevity platform co-founded by Dr. Ben Goertzel and Jasmine Smith, dedicated to accelerating healthy lifespan through decentralized research and data collaboration. The platform connects individuals, clinics, and scientists through the Rejuve Longevity App, where users can track biomarkers, receive personalized insights, and contribute anonymized data to global aging research. By rewarding participation with RJV tokens, Rejuve.AI empowers people to own their health data, optimize their well-being, and participate in the discovery of rejuvenation biomarkers and therapies. Its mission is to make longevity science accessible, participatory, and evidence-driven, bridging personal health optimization with collective intelligence for human rejuvenation.
Biomarkers of Aging Consortium is a global collaboration of scientists, clinicians, and technology innovators working to standardize and advance the measurement of biological aging. The consortium supports cross-disciplinary research integrating omics, clinical, and digital biomarkers to validate reliable indicators of aging and rejuvenation. Its mission is to accelerate translation from discovery to clinical application, enabling more effective evaluation of longevity interventions and the development of evidence-based rejuvenation therapies.
XPRIZE Foundation
XPRIZE is a global nonprofit that designs and hosts incentive competitions to catalyze radical breakthroughs for the benefit of humanity. Its mission is to accelerate transformative advancements across domains including health, longevity, energy, and climate by challenging innovators worldwide to solve grand challenges through public competition and collaboration. One of its flagship longevity-focused initiatives is the XPRIZE Healthspan, a multiyear, multi-million-dollar prize aimed at developing therapies that significantly extend human healthspan by restoring muscle, cognitive, and immune function in aging populations.
Buck Institute for Research on Aging
The Buck Institute for Research on Aging is the world’s first independent biomedical research institute dedicated exclusively to understanding the biology of aging and age-related diseases. Its mission is to extend the healthy years of life by advancing fundamental and translational science across mechanisms of aging, metabolism, neurodegeneration, senescence, and more. The Buck brings together leading scientists to push the frontiers of aging research and translate discoveries into interventions that improve healthspan and reduce the burden of age-related conditions.
AgeRate
AgeRate provides rapid, accessible biological age testing using next-generation epigenetic algorithms. Their mission is to empower individuals and researchers with reliable, science-backed longevity metrics to track aging and guide interventions.
Eveda
Eveda offers advanced preventative health and longevity diagnostics, integrating functional testing, biological age analysis, and personalized health planning. Their approach focuses on early detection, precision insights, and optimized pathways to healthier aging.
Deleón Omics
Deleón Omics is a cutting-edge molecular profiling and longevity analytics company specializing in metabolomics. Their work supports deep phenotyping and biomarker discovery essential for personalized longevity research.
& many more TBD.
